Can Coagulation System Disorders and Cytokine and Inflammatory Marker Levels Predict the Temporary Clinical Deterioration or Improvement of Septic Patients on ICU Admission?
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients and Protocol
2.2. Sample Collection and Laboratory Analysis
2.2.1. Determination of Inflammatory Markers
2.2.2. Determination of Cytokines
2.2.3. Determination of Coagulation Factors
2.3. Statistical Analysis
3. Results
3.1. Clinical and Laboratory Characteristics of Patients on ICU Admission
3.2. Measurements of the Coagulation Components, Cytokines, and Inflammatory Markers of Patients on ICU Admission
3.3. Predictive Value, in the Sense of Patient Temporary Clinical Deterioration or Improvement, of the Various Factors and Variables Measured on ICU Admission
3.3.1. Clinical and Laboratory Variables
3.3.2. Coagulation System, Cytokines, and Markers of Inflammation
4. Discussion
4.1. Usual Laboratory Parameters and Severity Scores
4.1.1. SOFA Score
4.1.2. APACHE II Score
4.1.3. PaO2/FiO2 Ratio and Lung Injury Score
4.1.4. Lactic Acid
4.2. Coagulation System
4.2.1. Platelets
4.2.2. Prothrombin Time (PT)
4.2.3. Antithrombin III
4.2.4. Protein C
4.2.5. Coagulation Factors FVII and FIX
4.3. Cytokines
4.3.1. Interleukin 1b, 6 and 10
4.3.2. TNF-a
4.4. Inflammatory Markers
4.5. Strengths and Limitations
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Declarations
Abbreviations
ICU | Intensive care unit |
SIRS | Systemic inflammatory response syndrome |
PCT | Procalcitonin |
CRP | C-reactive protein |
TPO | Thrombopoietin |
TNF-a | Tumor Necrosis Factor a |
IL-6 | Interleukin 6 |
IL-1b | Interleukin 1β |
IL-10 | Interleukin 10 |
ATIII | Antithrombin III |
PrC | Protein C |
Dds | D-dimmers |
Fibrin | Fibrinogen |
vWF | Ccoagulation factor vWillebrand |
WBC | White blood cells |
RBC | Red blood cells |
Ht | Hematocrit |
PTL | Platelets |
Creatin | Creatinine |
Bil | Bilirubin |
PT | Prothrombin time |
a-PTT | Activated partial thromboplastin time |
Lactate | Lactic acid |
Glu | Glucose |
Alb | Albumin |
APACHE | Acute physiology and chronic health evaluation |
MODS | Multiple organ dysfunction syndrome |
SOFA | Sequential organ failure assessment |
LIS | Lung injury score |
ARDS | Acute respiratory distress syndrome |
ROC | Receiver operating characteristic |
AUROC | Area under the ROC |
References
- Perner, A.; Gordon, A.A.; De Backer, D.; Dimopoulos, G.; Russell, J.A.; Lipman, J.; Jensen, J.U.S.; Myburgh, J.; Singer, M.; Bellomo, R.; et al. Sepsis: Frontiers in diagnosis, resuscitation and antibiotic therapy. Intens. Care Med. 2016, 42, 1958–1969. [Google Scholar] [CrossRef]
- Paoli, C.J.; Reynolds, M.A.; Sinha, M.; Gitlin, M.; Crouser, E. Epidemiology and costs of sepsis in the United States—An analysis based on timing of diagnosis and severity level. Crit. Care Med. 2018, 46, 1889–1897. [Google Scholar] [CrossRef] [PubMed]
- Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 1992, 20, 864–874. [CrossRef]
- Adhikari, N.K.; Fowler, R.A.; Bhagwanjee, S.; Rubenfeld, G.D. Critical care and the global burden of critical illness in adults. Lancet 2010, 376, 1339–1346. [Google Scholar] [CrossRef]
- Dellinger, R.P.; Carlet, J.M.; Masur, H.; Gerlach, H.; Calandra, T.; Cohen, J.; Gea-Banacloche, J.; Keh, D.; Marshall, J.C.; Parker, M.M.; et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit. Care Med. 2004, 32, 858–873. [Google Scholar] [CrossRef] [PubMed]
- Dellinger, R.P.; Levy, M.M.; Carlet, J.M.; Bion, J.; Parker, M.M.; Jaeschke, R.; Reinhart, K.; Angus, D.C.; Brun-Buisson, C.; Beale, R.; et al. Surviving Sepsis Capmaign: International guidelines for management of severe sepsis and septic shock: 2008. Intens. Care Med. 2008, 34, 17–60. [Google Scholar] [CrossRef] [Green Version]
- Singer, M.; Deutschman, C.S.; Seymour, C.W.; Shankar-Hari, M.; Annane, D.; Bellomo, R.; Bernard, G.B.; Chiche, J.D.; Coopersmith, C.M.; Hotchkiss, R.S.; et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis—3). JAMA 2016, 315, 801–810. [Google Scholar] [CrossRef]
- Seymour, C.W.; Liu, V.X.; Iwashyna, T.J.; Brunkhorst, F.M.; Rea, T.D.; Scherag, A.; Rubenfeld, G.; Kahn, J.M.; Shankar-Hari, M.; Singer, M.; et al. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016, 315, 762–774. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shankar-Hari, M.; Phillips, G.S.; Levy, M.L.; Seymour, C.W.; Liu, V.X.; Deutschman, C.S.; Angus, D.C.; Rubenfeld, G.D.; Singer, M. Assessment of definition and clinical criteria for septic shock. JAMA 2016, 315, 775–787. [Google Scholar] [CrossRef]
- Simpson, S.Q. SIRS in the Time of Sepsis-3. Chest 2018, 153, 34–38. [Google Scholar] [CrossRef] [Green Version]
- Mavrommatis, A.C.; Theodoridis, T.; Economou, M.; Kotanidou, A.; El Ali, M.; Christopoulou-Kokkinou, B.; Zakynthinos, S.G. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: Comparison with severe sepsis and septic shock. Intens. Care Med. 2001, 27, 1853–1859. [Google Scholar] [CrossRef]
- Strieter, R.M.; Kunkel, S.L.; Bone, R.C. Role of tumour necrosis factor-alpha in disease states and inflammation. Crit. Care Med. 1993, 21, S447–S463. [Google Scholar] [CrossRef] [PubMed]
- Zakynthinos, S.G.; Papanikolaou, S.; Theodoridis, T.; Zakynthinos, E.G.; Christopoulou-Kokkinou, V.; Katsaris, G.; Mavrommatis, A.C. Sepsis severity is the major determinant of circulating thrombopoietin levels in septic patients. Crit. Care Med. 2004, 32, 1004–1010. [Google Scholar] [CrossRef] [PubMed]
- Knaus, W.A.; Draper, E.A.; Wanger, D.; Zimmerman, J. APACHE II: A severity of disease classification system. Crit. Care Med. 1985, 13, 818–829. [Google Scholar] [CrossRef] [PubMed]
- Marshall, J.C.; Cook, D.J.; Christou, N.V.; Bernard, G.B.; Sprung, C.L.; Sibbald, W.J. Multiple Organ Disfunction Score. A reliable descriptor of a complex clinical outcome. Crit. Care Med. 1995, 23, 1638–1652. [Google Scholar] [CrossRef]
- Vincent, J.L.; de Mondonca, A.; Cantraine, F.; Moreno, R.; Takala, J.; Suter, P.M.; Sprung, C.L.; Colardyn, F.; Blecher, S. Use of SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicenter, prospective study. Crit. Care Med. 1998, 26, 1793–1800. [Google Scholar] [CrossRef] [PubMed]
- Murray, J.F.; Matthay, M.A.; Luce, J.M.; Flick, M.R. An expanded definition of the adult respiratory distress syndrome. Am. Rev. Resp. Dis. 1988, 138, 720–723. [Google Scholar] [CrossRef]
- Hanley, J.A.; McNeil, B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143, 29–36. [Google Scholar] [CrossRef] [Green Version]
- Ranieri, V.M.; Rubenfeld, G.D.; Thompson, B.T.; Ferguson, N.D.; Caldwell, E.; Fan, E.; Camporota, L.; Slutsky, A.S. ARDS Definition Task Force. Acute respiratory distress syndrome: The Berlin definition. JAMA 2012, 307, 2526–2533. [Google Scholar] [PubMed]
- Vincent, J.L.; Moreno, R.; Takala, J.; Willatts, S.; De Mendonça, A.; Bruining, H.; Reinhart, C.K.; Suter, P.M.; Thijs, L.G. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intens. Care Med. 1996, 22, 707–710. [Google Scholar] [CrossRef]
- Ferreira, F.L.; Bota, D.P.; Bross, A.; Mélot, C.; Vincent, J.L. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001, 286, 1754–1758. [Google Scholar] [CrossRef] [Green Version]
- Chen, F.G.; Koh, K.F. Septic shock in a surgical intensive care—Validation of multiorgan and APACHE II scores in predicting outcome. Ann. Acad. Med. 1994, 23, 447–451. [Google Scholar]
- Ho, K.M.; Dobb, G.J.; Knuiman, M.; Finn, J.; Lee, K.Y.; Webb, S.A. A comparison of admission and worst 24-hour Acute Physiology and Chronic Health Evaluation II scores in predicting hospital mortality: A retrospective cohort study. Crit Care 2006, 10, R4. [Google Scholar] [CrossRef] [Green Version]
- Wiskirchen, D.E.; Kuti, J.L.; Nicolau, D.P. Acute physiology and chronic health evaluation II score is a better predictor of mortality than IBMP-10 in patients with ventilator-associated pneumonia. Antimicrob. Agents Chemother. 2011, 55, 4170–4175. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mann, S.L.; Marshall, M.R.; Holt, A.; Woodford, B.; Williams, A.B. Illness severity scoring for Intensive Care at Middlemore Hospital, New Zealand: Past and future. N. Z. Med. J. 2010, 123, 47–65. [Google Scholar]
- Bhadade, R.R.; de Souza, R.A.; Harde, M.J.; Khot, A. Clinical characteristics and outcomes of patients with acute lung injury and ARDS. J. Postgrad. Med. 2011, 57, 286–290. [Google Scholar] [CrossRef] [PubMed]
- Atabai, K.; Matthay, M.A. The pulmonary physician in critical care. 5: Acute lung injury and the acute respiratory distress syndrome: Definitions and epidemiology. Thorax 2002, 57, 452–458. [Google Scholar] [CrossRef] [Green Version]
- Krishna, U.; Joshi, S.P.; Modh, M. An evaluation of serial blood lactate measurement as an early predictor of shock and its outcome in patients of trauma or sepsis. Indian J.Crit. Care Med. 2009, 13, 66–73. [Google Scholar] [CrossRef]
- Antonelli, M.; Levy, M.; Andrews, P.J.; Chastre, J.; Hudson, L.D.; Manthous, C.; Meduri, G.U.; Moreno, R.P.; Putensen, C.; Stewart, T.; et al. Hemodynamic monitoring in shock and implications for management. Intens. Care Med. 2007, 33, 575–590. [Google Scholar] [CrossRef] [PubMed]
- Rivers, E.; Nguyen, B.; Havstad, S.; Ressler, J.; Muzzin, A.; Knoblich, B.; Peterson, E.; Tomlanovich, M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 2001, 345, 1368–1377. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dellinger, R.P.; Levy, M.M.; Carlet, J.M.; Bion, J.; Parker, M.M.; Jaeschke, R.; Reinhart, K.; Angus, D.C.; Brun-Buisson, C.; Beale, R.; et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med. 2008, 36, 296–327. [Google Scholar] [CrossRef] [Green Version]
- Meregalli, A.; Oliveira, R.P.; Friedman, G. Occult hypoperfusion is associated with increased mortality in hemodynamically stable, high-risk, surgical patients. Crit Care 2004, 8, R60–R65. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vincent, J.L.; Dufaye, P.; Berré, J.; Leeman, M.; Degaute, J.P.; Kahn, R.J. Serial lactate determinations during circulatory shock. Crit. Care Med. 1983, 11, 449–451. [Google Scholar] [CrossRef]
- Abramson, D.; Scalea, T.M.; Hitchcock, R.; Trooskin, S.Z.; Henry, S.M.; Greenspan, J. Lactate clearance and survival following injury. J Trauma 1993, 35, 584–588. [Google Scholar] [CrossRef] [PubMed]
- Vervloet, M.G.; Thijs, L.G.; Hack, C.E. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin.Thromb. Hemost. 1998, 24, 33–44. [Google Scholar] [CrossRef] [PubMed]
- Heffner, J.E. Platelet-neutrophil interactions in sepsis—Platelet guilt by association? Intens. Care Med. 1997, 23, 366–368. [Google Scholar] [CrossRef] [PubMed]
- Gawaz, M.; Fateh-Moghadam, S.; Pilz, G.; Gurland, H.J.; Werdan, K. Platelet activation and interaction with leucocytes in patients with sepsis or multiple organ failure. Eur. J. Clin. Investig. 1995, 25, 843–851. [Google Scholar] [CrossRef] [PubMed]
- Gawaz, M.; Dickfeld, T.; Bogner, C.; Fateh-Moghadam, S.; Neumann, F.J. Platelet function in septic multiple organ dysfunction syndrome. Intens. Care Med. 1997, 23, 379–385. [Google Scholar] [CrossRef]
- Taniguchi, T.; Takagi, D.; Takeyama, N.; Kitazawa, Y.; Tanaka, T. Platelet size and function in septic rats: Changes in the adenylate pool. J. Surg. Res. 1990, 49, 400–407. [Google Scholar] [CrossRef]
- Edward, G.; Wittels, R.; Siegel, D.; Eric, M. Mazur Thrombocytopenia in the Intensive Care Unit Setting. J. Intens. Care Med. 1990, 5, 224–240. [Google Scholar]
- François, B.; Trimoreau, F.; Vignon, P.; Fixe, P.; Praloran, V.; Gastinne, H. Thrombocytopenia in the sepsis syndrome: Role of hemophagocytosis and macrophage colony-stimulating factor. Am. J. Med. 1997, 103, 114–120. [Google Scholar] [CrossRef]
- Akca, S.; Haji-Michael, P.; de Mendonça, A.; Suter, P.; Levi, M.; Vincent, J.L. Time course of platelet counts in critically ill patients. Crit. Care Med. 2002, 30, 753–756. [Google Scholar] [CrossRef] [PubMed]
- Stéphan, F.; Hollande, J.; Richard, O.; Cheffi, A.; Maier-Redelsperger, M.; Flahault, A. Thrombocytopenia in a surgical ICU. Chest 1999, 115, 1363–1370. [Google Scholar] [CrossRef]
- Brun-Buisson, C.; Doyon, F.; Carlet, J.; Dellamonica, P.; Gouin, F.; Lepoutre, A.; Mercier, J.C.; Offenstadt, G.; Régnier, B. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995, 274, 968–974. [Google Scholar] [CrossRef]
- Breslow, A.; Kaufman, R.M.; Lawsky, A.R. The effect of surgery on the concentration of circulating megakaryocytes and platelets. Blood 1968, 32, 393–401. [Google Scholar] [CrossRef] [Green Version]
- Fagher, B.; Sjögren, A.; Sjögren, U. Platelet counts in myocardial infarction, angina pectoris and peripheral artery disease. Acta Med. Scand. 1985, 217, 21–26. [Google Scholar] [CrossRef] [PubMed]
- Nijsten, M.W.; ten Duis, H.J.; Zijlstra, J.G.; Porte, R.J.; Zwaveling, J.H.; Paling, J.C.; The, T.H. Blunted rise in platelet count in critically ill patients is associated with worse outcome. Crit. Care Med. 2000, 28, 3843–3846. [Google Scholar] [CrossRef] [PubMed]
- Smith-Erichsen, N. Serial determinations of platelets, leucocytes and coagulation parameters in surgical septicemia. Scand. J. Clin. Lab. Investig. 1985, 178, S7–S14. [Google Scholar]
- Dhainaut, J.F.; Shorr, A.F.; Macias, W.L.; Kollef, M.J.; Levi, M.; Reinhart, K.; Nelson, D.R. Dynamic evolution of coagulopathy in the first day of severe sepsis: Relationship with mortality and organ failure. Crit. Care Med. 2005, 33, 341–348. [Google Scholar] [CrossRef] [Green Version]
- Leithauser, B.; Matthias, F.R.; Nicolai, U.; Voss, R. Hemostaticabnormalities and the severity of illness in patients at the onset of clinically defined sepsis. Possible indication of the degree of endothelial cell activation. Intens. Care Med. 1996, 22, 631–636. [Google Scholar] [CrossRef]
- Gando, S.; Smanzaki, S.; Sasaki, S.; Aoi, K.; Kemmotsu, O. Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Crit. Care Med. 1998, 26, 2005–2009. [Google Scholar] [CrossRef] [PubMed]
- Li, J.J.; Sanders, R.L.; McAdam, K.P.; Hales, C.A.; Thompson, B.T.; Gelfand, J.A.; Burke, J.F. Impact of C-reactive protein (CPR) on surfactant function. J. Trauma 1989, 29, 1690–1697. [Google Scholar] [CrossRef] [PubMed]
- Opal, S.M.; Kessler, C.M.; Roemisch, J.; Knaub, S. Antithrombin, heparinand heparin sulphate. Crit. Care Med. 2002, 30, S5. [Google Scholar] [CrossRef]
- Fourrier, F.; Chopin, C.; Goudemand, J.; Hendrycx, S.; Caron, C.; Rime, A.; Marey, A.; Lestavel, P. Septic shock, multiple organ failure, and disseminated intravascular coagulation: Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992, 101, 816–823. [Google Scholar] [CrossRef] [PubMed]
- Oelschläger, C.; Römisch, J.; Staubitz, A.; Stauss, H.; Leithäuser, B.; Tillmanns, H.; Hölschermann, H. Antithrombin III inhibits nuclear factor κB activation in human monocytes and vascular endothelial cells. Blood 2002, 99, 4015–4020. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- McGee, M.P.; Foster, S.; Wang, X. Simultaneous expression of tissue factor pathway inhibitor by human monocytes. A potential mechanism for localized control of blood coagulation. J. Exp. Med. 1994, 179, 1847–1854. [Google Scholar] [CrossRef] [Green Version]
- Sprengers, E.D.; Kluft, C. Plasminogen activator inhibitors. Blood 1987, 69, 381–387. [Google Scholar] [CrossRef] [Green Version]
- Loskutoff, D.J.; Schleef, R.R. Plasminogen activators and their inhibitors. Methods Enzymol. 1988, 163, 293–302. [Google Scholar] [PubMed]
- Wilde, J.T.; Roberts, K.M.; Greaves, M.; Preston, F.E. Association between necropsy evidence of disseminated intravascular coagulation and coagulation variables before death in patients in intensive care units. J. Clin.Pathol. 1988, 41, 138–142. [Google Scholar] [CrossRef] [Green Version]
- Mavrommatis, A.C.; Theodoridis, T.; Orfanidou, A.; Roussos, C.; Christopoulou-Kokkinou, V.; Zakynthinos, S. Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit. Care Med. 2000, 28, 451–457. [Google Scholar] [CrossRef]
- Bernard, G.R.; Vincent, J.L.; Laterre, P.F.; LaRosa, S.P.; Dhainaut, J.F.; Lopez-Rodriguez, A.; Steingrub, J.S.; Garber, G.E.; Helterbrand, J.D.; Ely, E.W.; et al. Efficacy and safety of recombinant human activated protein C for severe sepsis; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. N. Engl. J. Med. 2001, 344, 699–709. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bozza, F.A.; Bozza, P.T.; Castro Faria Neto, H.C. Beyond sepsis pathophysiology with cytokines: What is their value as biomarkers for disease severity? Mem. Inst. Oswaldo Cruz 2005, 100, S217–S221. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gogos, C.A.; Drosou, E.; Bassaris, H.P.; Skoutelis, A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: A marker for prognosis and future therapeutic options. J. Infect. Dis. 2000, 181, 176–180. [Google Scholar] [CrossRef] [PubMed]
- Pinsky, M.R.; Vincent, J.L.; Deviere, J.; Alegre, M.; Kahn, R.J.; Dupont, E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993, 103, 565–575. [Google Scholar] [CrossRef]
- Tanaka, H.; Ishikawa, K.; Nishino, M.; Shimazu, T.; Yoshioka, T. Changes in granulocyte colony-stimulating factor concentration in patients with trauma and sepsis. J. Trauma 1996, 40, 718–725. [Google Scholar] [CrossRef]
- McAllister, S.K.; Bland, L.A.; Arduino, M.J.; Wenger, P.N.; Jarvis, W.R. Patient cytokine response in transfusion-associated sepsis. Infect. Immun. 1994, 62, 2126–2128. [Google Scholar] [CrossRef] [Green Version]
- Gerard, C.; Bruyns, C.; Marchant, A.; Abramowicz, D.; Vanderbeele, P.; Delvaux, A.; Fiers, W.; Goldman, M.; Velu, T. Interleukin-10 reduces the release of tumour necrosis factor and prevents lethality in experimental endotoxemia. J. Exp. Med. 1993, 177, 547–550. [Google Scholar] [CrossRef]
- Endo SInada, K.; Inoue, Y.; Kuwata, Y.; Suzuki, M.; Yamashita, H.; Hoshi, S.; Yoshida, M. Two types of septic shock classified by the plasma level of cytokines and endotoxin. Circ. Shock 1992, 38L, 264–267. [Google Scholar]
- Goldie, A.S.; Fearon, K.C.; Ross, J.A.; Barclay, G.R.; Jackson, R.E.; Grant, I.S.; Ramsay, G.; Blyth, A.S.; Howie, J.C. Natural cytokine antagonist and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. JAMA 1995, 274, 547–550. [Google Scholar] [CrossRef]
- Marchant, A.; Deviere, J.; Byl, B.; De Groote, D.; Vincent, J.L.; Goldman, M. Interleukin-10 production during septicaemia. Lancet 1994, 343, 707–708. [Google Scholar] [CrossRef]
- Van Deuren, M.; van der Ven-Jon Gekrijg, J.; Bartelink, A.K.M.; van Dalen, R.; Sauerwein, R.W.; van der Meer, J.W.M. Correlation between proinflammatory cytokines and anti-inflammatory mediators and the severity of disease in meningococcal infections. J. Infect. Dis. 1994, 172, 433–439. [Google Scholar] [CrossRef] [PubMed]
- Casey, L.C.; Balk, R.A.; Bone, R.C. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann. Intern. Med. 1993, 119, 771–778. [Google Scholar] [CrossRef]
- Martin, C.; SauzxPMege, J.L.; Perrin, G.; Papazian, L.; Gouin, F. Prognostic value of serum cytokines in septic shock. Intens. Care Med. 1994, 20, 272–277. [Google Scholar] [CrossRef] [PubMed]
- Assicot, M.; Gendrel, D.; Carsin, H.; Raymond, J.; Guilbaud, J.; Bohouon, C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993, 341, 515–518. [Google Scholar] [CrossRef]
- Brunkhorst, F.M.; Heinz, U.; Forycki, Z.F. Kinetics of procalcitonin in iatrogenic sepsis. Intens. Care Med. 1998, 24, 888–889. [Google Scholar] [CrossRef]
- De Werra, I.; Jaccard, C.; Corradin, S.B.; Chiolero, R.; Yersin, B.; Gallati, H. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: Comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit. Care Med. 1997, 25, 607–613. [Google Scholar] [CrossRef]
- Muller, B.; Becker, K.L.; Schachin ger, H.; Rickenbacher, P.R.; Huber, P.R.; Zimmerli, W. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit. Care Med. 2000, 28, 977–983. [Google Scholar] [CrossRef]
- Kaushansky, K. Thrombopoietin. N. Engl. J. Med. 1998, 339, 746–754. [Google Scholar] [CrossRef]
- Kuter, D.J.; Rosenberg, R.D. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995, 85, 2720–2730. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zeerleder, S.; Schroeder, V.; Lämmle, B.; Wuillemin, W.; Hack, C.E.; Kohler, H.P. Factor XIII in severe sepsis and septic shock. Thromb. Res. 2007, 119, 311–318. [Google Scholar] [CrossRef] [PubMed]
Τrauma–Surgery (n = 26) | SIRS (n = 17) | Sepsis (n = 14) | Severe Sepsis (n = 17) | Septic Shock (n = 28) | p a | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Median | Range | Median | Range | Median | Range | Median | Range | Median | Range | |||||||
Age (yrs) | 38 | 17 | 77 | 53 | 17 | 80 | 43 | 25 | 66 | 55 | 32 | 76 | 49 | 24 | 70 | 0.07 |
APACHE | 7.0 | 2.0 | 18.0 | 11.5b | 5.0 | 24.0 | 13.0b | 5.0 | 21.0 | 16.0b,c | 6.0 | 27.0 | 23.0b,c,d | 8.0 | 31.0 | <0.001 |
SOFA | 6.0 | 2.0 | 14.0 | 8.0 | 1.0 | 13.0 | 2.0b,c | 1.0 | 5.0 | 8.0b,d | 6.0 | 11.0 | 10.0b,c,d | 6.0 | 14.0 | <0.01 |
LIS | 0.6 | 0.0 | 2.0 | 1.0 | 0.0 | 3.3 | 0.6 | 0.0 | 2.0 | 1.8b,c,d | 0.60 | 2.9 | 1.9b,c,d | 0.2 | 3.9 | 0.04 |
PaO2/FiO2 (mmHg) | 301 | 90 | 647 | 186 | 110 | 587 | 166b | 132 | 337 | 112b,c,d | 66 | 326 | 111b,c,d | 70 | 325 | <0.01 |
MODS (yes/no) | 3/23 (12%) | 4/13 (24%) | 0/14 (0%) b,c | 7/10 (41%) b,c,d | 16/12 (57%) b,c,d,e | |||||||||||
Ht (%) | 29.0 | 19.6 | 43.4 | 29.2 | 19.0 | 41.8 | 30.0 | 24.0 | 35.8 | 30.5 | 24.3 | 35.0 | 27.5 | 15.0 | 36.5 | 0.71 |
PLT (×109/L) | 195 | 80 | 502 | 238 | 52 | 790 | 233 | 87 | 677 | 164c,d | 33 | 430 | 135b,c,d,e | 15 | 338 | <0.01 |
WBC (×109/L) | 9.1 | 5.7 | 20.4 | 10.6 | 3.6 | 24.0 | 13.4b | 6.3 | 33.0 | 14.5b | 4.4 | 39.1 | 17.3b,c,d | 6.4 | 41.3 | <0.01 |
Glucose (mg/dL) | 136 | 85 | 254 | 140 | 82 | 568 | 115 | 106 | 158 | 135 | 131 | 199 | 150 | 138 | 223 | 0.09 |
Lactate (mmol/L) | 1.3 | 0.7 | 6.7 | 2.0 | 0.7 | 4.9 | 1.9 | 0.6 | 3.5 | 1.6 | 0.7 | 3.0 | 3.7b,c,d,e | 0.8 | 8.9 | <0.01 |
Creatinin (mg/dL) | 0.8 | 0.5 | 2.7 | 0.9 | 0.4 | 4.9 | 0.9 | 0.6 | 4.1 | 1.8b,c,d | 0.7 | 5.2 | 1.9b,c,d | 0.4 | 9.0 | <0.01 |
Bil (mg/dL) | 0.6 | 0.2 | 2.4 | 0.7 | 0.1 | 2.6 | 1.1 | 0.4 | 5.2 | 1.5b,c,d | 0.5 | 14.2 | 1.6b,c,d | 0.2 | 18.9 | <0.01 |
Alb (g/dL) | 2.8 | 2.0 | 3.9 | 2.6 | 1.8 | 4.4 | 2.5 | 1.4 | 3.3 | 2.7 | 2.0 | 3.9 | 2.1b,c,d,e | 1.2 | 3.7 | 0.02 |
Τrauma–Surgery (n = 26) | SIRS (n = 17) | Sepsis (n = 14) | Severe Sepsis (n = 17) | Septic Shock (n = 28) | p a | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Median | Range | Median | Range | Median | Range | Median | Range | Median | Range | |||||||
PT (sec) | 14.0 | 12.2 | 21.6 | 13.9 | 12.4 | 22.0 | 15.4 | 12.8 | 19.7 | 16.5b,c | 13.1 | 27.2 | 17.8b,c | 13.6 | 25.7 | <0.01 |
a-PTT (sec) | 36.8 | 26.5 | 57.5 | 36.0 | 25.6 | 70.4 | 34.5 | 32.3 | 50.5 | 38.6 | 36.7 | 56.0 | 39.9 | 27.8 | 51.7 | 0.12 |
Fibrinogen (mg/dL) | 438 | 170 | 753 | 423 | 159 | 639 | 511 | 497 | 526 | 535 | 493 | 636 | 504 | 439 | 700 | 0.26 |
Dds (μg/mL) | 3.4 | 0.3 | 7.4 | 2.4 | 0.6 | 9.8 | 2.9 | 0.7 | 4.2 | 6.1b,c,d | 1.4 | 23.8 | 9.2b,c,d | 1.8 | 37.6 | <0.01 |
FVII (%) | 58.0 | 36.0 | 94.0 | 75.0b | 45.0 | 1410 | 86.4b | 44.8 | 137.7 | 61.3,c,d | 33.0 | 110.0 | 34.0b,c,d,e | 29.0 | 80.0 | <0.001 |
FIX (%) | 86.0 | 75.0 | 111.0 | 103.0 | 91.0 | 133.0 | 87.5 | 65.0 | 110.0 | 90.0 | 76.0 | 114.0 | 98.5 | 75.0 | 128.0 | 0.13 |
FVIII (%) | 117.0 | 67.0 | 146.0 | 123.0 | 55.6 | 151.0 | 121.0 | 88.0 | 146.0 | 110.0 | 71.6 | 148.0 | 114.0 | 81.0 | 162.0 | 0.35 |
vWF (%) | 148.5 | 134.0 | 200.0 | 111.0b | 95.0 | 177.0 | 114.5b | 81.0 | 173.0 | 128.0 | 82.0 | 158.0 | 136.5c,d | 85.0 | 461.0 | <0.001 |
FX (%) | 58.5 | 32.0 | 83.0 | 92.5b | 74.0 | 116.0 | 91.0b | 82.0 | 128.0 | 86.0b | 73.0 | 113.0 | 79.5b | 66.0 | 119.0 | <0.01 |
FV (%) | 73.0 | 29.0 | 133.0 | 97.0b | 55.0 | 136.0 | 105.0b | 61.0 | 129.0 | 95.0b | 61.0 | 117.0 | 76.0c,d,e | 34.0 | 111.0 | <0.01 |
ATIII (%) | 66.0 | 33.0 | 104.0 | 86.0b | 66.0 | 131.0 | 75.0b | 55.0 | 129.0 | 50.3b,c,d | 29.0 | 102.0 | 46.0b,c,d | 23.0 | 113.0 | <0.001 |
PrC (%) | 76.5 | 33.0 | 120.0 | 77.0 | 49.0 | 119.6 | 81.0 | 57.0 | 141.0 | 79.1 | 34.0 | 149.5 | 58.0b,c,d,e | 12.0 | 125.0 | <0.01 |
Plasminogen (%) | 75.3 | 50.0 | 97.0 | 62.0 | 32.0 | 96.0 | 71.3 | 46.8 | 101.4 | 63.4 | 45.0 | 93.8 | 58.7 | 46.3 | 109.0 | 0.08 |
TNF-a (pg/mL) | 1.2 | 0.0 | 9.7 | 2.8 | 0.7 | 5.0 | 2.9 | 0.5 | 5.4 | 3.1 | 1.2 | 5.1 | 4.9b,c,d | 1.0 | 8.4 | 0.02 |
IL-1b (pg/mL) | 0.2 | 0.0 | 1.9 | 0.2 | 0.1 | 3.9 | 0.2 | 0.1 | 1.5 | 1.9 | 0.7 | 3.1 | 2.9b,c,d | 0.2 | 10.2 | 0.04 |
IL-10 (pg/mL) | 5.1 | 1.2 | 450.7 | 9.8b | 1.9 | 438.2 | 10.9b | 2.9 | 123.5 | 11.8b | 1.77 | 211.8 | 12.1b | 2.1 | 285.9 | 048 |
IL-6 (pg/mL) | 22.2 | 8.6 | 70.9 | 24.0 | 17.5 | 127.4 | 26.6 | 20.1 | 112.0 | 29.2 | 19.2 | 120.2 | 31.6 | 16.7 | 128.6 | 0.22 |
CRP (mg/dL) | 12.3 | 0.1 | 26.0 | 8.9 | 1.6 | 30.9 | 17.3 | 0.4 | 49.7 | 22.1b,c | 10.1 | 50.3 | 27.9b,c,d | 5.3 | 73.0 | <0.01 |
PCT (ng/mL) | 1.0 | 0.0 | 31.6 | 0.7 | 0.1 | 10.0 | 0.5 | 0.1 | 43.3 | 5.7b,c,d | 0.2 | 130.7 | 4.4b,c,d | 0.3 | 110.8 | <0.01 |
TPO (pg/mL) | 147 | 11 | 583 | 132 | 21 | 2570 | 142 | 38 | 1160 | 492b,c,d | 40 | 1344 | 530b,c,d | 42 | 2213 | <0.01 |
Patients Who Deteriorated (n = 12) | Patients Who Improved (n = 14) | p a | |||||
---|---|---|---|---|---|---|---|
Median | Range | Median | Range | ||||
Age (yrs) | 32 | 17 | 77 | 50 | 22 | 77 | 0.16 |
APACHE | 8.0 | 4.0 | 16.5 | 7.0 | 1.5 | 18.0 | 0.15 |
SOFA | 7.0 | 4.0 | 14.0 | 5.5 | 2.0 | 7.0 | 0.15 |
LIS | 1.0 | 0.0 | 2.0 | 0.3 | 0.0 | 2.0 | 0.09 |
PaO2/FiO2 (mmHg) | 201 | 90 | 542 | 350 | 148 | 647 | 0.04 |
MODS (yes/no) | 2/10 (17%) | 1/13 (7%) | 0.58 b | ||||
Ht (%) | 27.7 | 19.6 | 39.9 | 31.0 | 28.2 | 43.4 | 0.11 |
PLT (×109/L) | 131 | 80 | 502 | 226 | 120 | 337 | 0.09 |
WBC (×109/L) | 8.6 | 5.7 | 20.4 | 12.3 | 7.9 | 19.6 | 0.08 |
Glu (mg/dL) | 128 | 111 | 221 | 140 | 85 | 254 | 0.95 |
Lactate (mmol/L) | 1.5 | 0.9 | 6.7 | 1.2 | 0.7 | 2.9 | 0.74 |
Creatin (mg/dL) | 0.7 | 0.5 | 2.7 | 0.9 | 0.6 | 1.8 | 0.28 |
Bil (mg/dL) | 0.7 | 0.2 | 2.3 | 0.5 | 0.4 | 2.4 | 0.90 |
Alb (g/dL) | 3.0 | 2.2 | 3.9 | 2.5 | 2.0 | 3.6 | 0.92 |
PT (sec) | 15.2 | 12.9 | 21.6 | 12.6 | 12.2 | 15.5 | <0.001 |
a-PTT (sec) | 39.8 | 28.00 | 57.5 | 33.6 | 26.5 | 44.4 | 0.39 |
Fibrin (mg/dL) | 351 | 170 | 753 | 457 | 322 | 622 | 0.52 |
Dds (μg/mL) | 4.6 | 0.6 | 7.4 | 3.0 | 0.3 | 3.2 | 0.04 |
FVII (%) | 46.5 | 26.00 | 94.0 | 65.0 | 35 | 94 | 0.25 |
FIX (%) | 84.0 | 75.00 | 107.0 | 93.0 | 79.0 | 111.0 | 0.33 |
FVIII (%) | 101.5 | 67.00 | 146.0 | 120.0 | 73.0 | 140.0 | 0.04 |
vWF (%) | 150.0 | 142.5 | 200.0 | 147.0 | 134.0 | 195.0 | 0.84 |
FX (%) | 51.2 | 32.00 | 83.0 | 60.0 | 50.00 | 76.0 | 0.54 |
FV (%) | 66.0 | 29.00 | 130.0 | 81.0 | 43.00 | 133.0 | 0.28 |
ATIII (%) | 64.0 | 33.00 | 104.0 | 72.9 | 51.0 | 99.0 | 0.90 |
PrC (%) | 72.0 | 33.0 | 115.0 | 77.5 | 65.00 | 120.0 | 0.60 |
Plasminogen (%) | 59.0 | 50.0 | 97.0 | 78.0 | 63.1 | 83.0 | 0.12 |
TNF-a (pg/mL) | 2.1 | 1.3 | 9.7 | 0.9 | 0.00 | 1.3 | <0.001 |
IL-1b (pg/mL) | 0.2 | 0.1 | 1.8 | 0.2 | 0.00 | 1.9 | 0.94 |
IL-10 (pg/mL) | 6.7 | 1.6 | 356.3 | 4.8 | 1.2 | 450.7 | 0.49 |
IL-6 (pg/mL) | 23.2 | 12.0 | 53.0 | 21.0 | 8.6 | 70.9 | 0.41 |
CRP (mg/dL) | 12.8 | 2.3 | 22.1 | 11.9 | 0.1 | 26.0 | 0.69 |
PCT (ng/mL) | 1.1 | 0.21 | 24.5 | 0.6 | 0.0 | 31.6 | 0.65 |
TPO (pg/mL) | 177 | 33 | 583 | 127 | 11 | 367 | 0.60 |
Patients Who Deteriorated (n = 13) | Patients Who Improved (n = 4) | p a | |||||
---|---|---|---|---|---|---|---|
Median | Range | Median | Range | ||||
Age (yrs) | 48 | 17 | 80 | 56 | 43 | 69 | 0.35 |
APACHE | 11.5 | 5.0 | 24.0 | 14.5 | 8.0 | 22.0 | 0.62 |
SOFA | 8.0 | 1.0 | 66.0 | 9.5 | 6.0 | 10.0 | 0.62 |
LIS | 1.3 | 0.0 | 3.3 | 0.6 | 0.3 | 2.0 | 0.52 |
PaO2/FiO2 (mmHg) | 164 | 46 | 587 | 226 | 136 | 280 | 0.04 |
MODS (yes/no) | 4/9 (31%) | 0/4 (0%) | 0.51 b | ||||
Ht (%) | 29.2 | 19.0 | 41.5 | 36.7 | 28.9 | 41.8 | 0.13 |
PLT (×109/L) | 152 | 52 | 279 | 179 | 140 | 790 | 0.24 |
WBC (×109/L) | 10.6 | 3.6 | 16.0 | 10.9 | 9.0 | 24.0 | 0.62 |
Glu (mg/dL) | 140 | 108 | 568 | 156 | 82 | 311 | 1.00 |
Lactate (mmol/L) | 2.0 | 0.7 | 4.9 | 2.0 | 1.3 | 2.2 | 0.86 |
Creatin (mg/dL) | 0.9 | 0.4 | 4.9 | 0.9 | 0.7 | 1.2 | 0.70 |
Bil (mg/dL) | 0.7 | 0.3 | 2.6 | 0.8 | 0.1 | 1.4 | 0.87 |
Alb (g/dL) | 2.5 | 1.8 | 4.4 | 2.8 | 1.8 | 3.9 | 0.75 |
PT (sec) | 13.9 | 12.4 | 22.0 | 14.6 | 13.1 | 16.4 | 0.78 |
a-PTT (sec) | 36.6 | 25.6 | 70.4 | 34.4 | 30.3 | 38.5 | 0.41 |
Fibrin (mg/dL) | 478 | 159 | 639 | 336 | 292 | 405 | 0.10 |
Dds (μg/mL) | 3.1 | 0.6 | 9.8 | 1.6 | 0.8 | 2.4 | 0.66 |
FVII (%) | 63.5 | 45.0 | 119.0 | 78.0 | 75.0 | 141.0 | 0.28 |
FIX (%) | 103.0 | 92.0 | 133.0 | 105.0 | 91.0 | 119.0 | 0.80 |
FVIII (%) | 122.5 | 55.6 | 140.0 | 126.0 | 81.0 | 151.0 | 0.57 |
vWF (%) | 104.0 | 95.0 | 177.0 | 127.0 | 99.0 | 150.0 | 0.20 |
FX (%) | 86.5 | 74.0 | 105.0 | 102.5 | 89.0 | 116.0 | 0.53 |
FV (%) | 65.0 | 55.0 | 136.0 | 110.0 | 79.0 | 126.0 | 0.07 |
ATIII (%) | 74.0 | 66.0 | 86.0 | 102.0 | 85.0 | 131.0 | 0.57 |
PrC (%) | 73.5 | 49.0 | 119.6 | 87.0 | 52.0 | 108.5 | 0.69 |
Plasminogen (%) | 66.5 | 32.0 | 96.0 | 59.4 | 44.7 | 91.0 | 0.67 |
TNF-a (pg/mL) | 2.9 | 0.7 | 5.0 | 2.6 | 0.8 | 4.9 | 1.00 |
IL-1b (pg/mL) | 0.4 | 0.1 | 3.9 | 0.2 | 0.2 | 3.4 | 0.69 |
IL-10 (pg/mL) | 8.6 | 1.9 | 80.0 | 58.8 | 9.8 | 438.2 | 0.13 |
IL-6 (pg/mL) | 22.0 | 17.5 | 127.4 | 26.6 | 13.7 | 113.8 | 0.81 |
CRP (mg/dL) | 8.3 | 1.6 | 30.9 | 9.9 | 2.4 | 17.4 | 0.60 |
PCT (ng/mL) | 1.0 | 0.10 | 10.0 | 0.4 | 0.3 | 0.6 | 0.52 |
TPO (pg/mL) | 95.0 | 21 | 2570 | 338 | 126 | 941 | 0.22 |
Patients Who Deteriorated (n = 10) | Patients Who Improved (n = 4) | p a | |||||
---|---|---|---|---|---|---|---|
Median | Range | Median | Range | ||||
Age (yrs) | 45 | 29 | 58 | 35 | 25 | 66 | 0.46 |
APACHE | 14.0 | 6.0 | 21.0 | 7.6 | 5.0 | 10.0 | <0.01 |
SOFA | 3.5 | 2.0 | 5.0 | 1.5 | 1.0 | 2.0 | 0.01 |
LIS | 1.5 | 0.5 | 2.0 | 0.4 | 0.0 | 1.8 | 0.03 |
PaO2/FiO2 (mmHg) | 183 | 132 | 211 | 315 | 154 | 337 | 0.08 |
MODS (yes/no) | 0/10 (0%) | 0/4 (0%) | 1.00 b | ||||
Ht (%) | 27.9 | 24.0 | 35.8 | 32.1 | 25.0 | 34.2 | 0.32 |
PLT (×109/L) | 195 | 87 | 462 | 267 | 194 | 677 | 0.09 |
WBC (×109/L) | 12.5 | 6.3 | 21.0 | 14.7 | 8.3 | 33.0 | 0.83 |
Glu (mg/dL) | 122 | 106 | 158 | 112 | 108 | 126 | 0.65 |
Lactate (mmol/L) | 1.4 | 0.9 | 3.5 | 2.1 | 0.6 | 2.6 | 0.21 |
Creatin (mg/dL) | 1.0 | 0.6 | 4.1 | 0.8 | 0.7 | 1.4 | 0.08 |
Bil (mg/dL) | 1.2 | 0.4 | 5.2 | 1.0 | 0.5 | 2.5 | 0.34 |
Alb (g/dL) | 2.3 | 1.4 | 3.3 | 2.8 | 2.5 | 3.3 | 0.26 |
PT (sec) | 15.6 | 13.5 | 19.7 | 14.5 | 12.8 | 17.9 | 0.14 |
a-PTT (sec) | 38.6 | 33.6 | 45.4 | 34.0 | 32.3 | 50.5 | 0.07 |
Fibrin (mg/dL) | 516 | 497 | 518 | 498 | 480 | 526 | 0.97 |
Dds (μg/mL) | 2.7 | 1.4 | 4.2 | 3.0 | 0.7 | 4.0 | 0.84 |
FVII (%) | 89.0 | 44.8 | 97.0 | 101.0 | 73.0 | 137.7 | 0.23 |
FIX (%) | 84.7 | 75.0 | 106.0 | 96.0 | 65.0 | 110.0 | 0.37 |
FVIII (%) | 132.3 | 90.3 | 146.0 | 102.7 | 88.0 | 134.5 | 0.79 |
vWF (%) | 108.0 | 81.0 | 170.3 | 139.0 | 124.0 | 173.0 | 0.16 |
FX (%) | 89.0 | 82.0 | 125.0 | 95.5 | 89.0 | 128.0 | 0.58 |
FV (%) | 89.5 | 67.8 | 108.9 | 115.8 | 61.0 | 129.0 | 0.41 |
ATIII (%) | 78.8 | 55.0 | 120.5 | 83.1 | 57.0 | 141.0 | 0.24 |
PrC (%) | 68.3 | 5.0 | 138.2 | 85.0 | 37.0 | 168.4 | 0.40 |
Plasminogen (%) | 78.8 | 71.7 | 100.1 | 64.4 | 46.8 | 101.4 | 0.47 |
TNF-a (pg/mL) | 4.9 | 0.8 | 5.4 | 1.1 | 0.5 | 2.3 | 0.02 |
IL-1b (pg/mL) | 1.2 | 0.4 | 1.5 | 0.3 | 0.1 | 0.7 | <0.001 |
IL-10 (pg/mL) | 17.4 | 3.3 | 123.5 | 3.4 | 2.9 | 10.0 | <0.001 |
IL-6 (pg/mL) | 24.0 | 11.0 | 26.4 | 31.5 | 20.1 | 112.0 | 0.82 |
CRP (mg/dL) | 19.6 | 5.1 | 49.7 | 11.9 | 0.4 | 16.9 | 0.08 |
PCT (ng/mL) | 1.1 | 0.1 | 39.0 | 0.3 | 0.1 | 43.3 | 0.44 |
TPO (pg/mL) | 168 | 23 | 1160 | 124 | 38 | 397 | 0.25 |
Patients Who Deteriorated (n = 9) | Patients Who Improved (n = 8) | p a | |||||
---|---|---|---|---|---|---|---|
Median | Range | Median | Range | ||||
Age (yrs) | 70 | 32 | 76 | 40 | 33 | 74 | 0.03 |
APACHE | 19.0 | 11.0 | 27.0 | 13.0 | 6.0 | 21.0 | <0.01 |
SOFA | 9.5 | 7.0 | 11.0 | 7.5 | 6.0 | 11.0 | 0.04 |
LIS | 2.6 | 0.6 | 2.9 | 1.3 | 0.6 | 2.0 | 0.03 |
PaO2/FiO2 (mmHg) | 96 | 66 | 326 | 281 | 136 | 320 | <0.01 |
MODS (yes/no) | 5/4(56%) | 2/6 (25%) | 0.33 b | ||||
Ht (%) | 29.5 | 24.3 | 34.5 | 32.7 | 25.00 | 35.0 | 0.67 |
PLT (×109/L) | 140 | 33 | 230 | 187 | 93 | 430 | 0.54 |
WBC (×109/L) | 12.4 | 6.9 | 19.9 | 16.3 | 4.4 | 39.1 | 0.96 |
Glu (mg/dL) | 133 | 131 | 197 | 149 | 135 | 199 | 1.00 |
Lactate (mmol/L) | 2.5 | 1.6 | 3.0 | 1.1 | 0.7 | 2.0 | 0.07 |
Creatin (mg/dL) | 2.3 | 0.7 | 5.2 | 1.7 | 0.7 | 2.0 | 0.08 |
Bil (mg/dL) | 3.5 | 0.6 | 14.2 | 0.8 | 0.5 | 3.5 | 0.06 |
Alb (g/dL) | 2.4 | 2.0 | 2.9 | 2.9 | 1.80 | 3.9 | 0.87 |
PT (sec) | 17.5 | 13.6 | 27.2 | 14.3 | 13.1 | 19.7 | 0.22 |
a-PTT (sec) | 42.3 | 36.7 | 56.0 | 35.0 | 37.8 | 51.7 | 0.23 |
Fibrin (mg/dL) | 514 | 493 | 600 | 542 | 499 | 636 | 1.00 |
Dds (μg/mL) | 7.8 | 1.4 | 23.8 | 4.5 | 1.8 | 6.2 | 0.65 |
FVII (%) | 41.0 | 33.0 | 65.0 | 66.0 | 45.0 | 110.0 | 0.06 |
FIX (%) | 84.0 | 76.0 | 104.0 | 107.5 | 96.0 | 114.0 | 0.09 |
FVIII (%) | 104.0 | 71.6 | 145.0 | 122.0 | 81.6 | 148.0 | 0.39 |
vWF (%) | 99.0 | 82.0 | 158.0 | 130.5 | 114.00 | 134.0 | 0.67 |
FX (%) | 79.0 | 73.0 | 112.0 | 99.5 | 90.0 | 113.0 | 0.62 |
FV (%) | 85.0 | 61.0 | 117.0 | 101.0 | 81.0 | 115.0 | 0.98 |
ATIII (%) | 33.2 | 29.0 | 70.0 | 66.0 | 40.3 | 102.0 | 0.02 |
PrC (%) | 44.0 | 34.0 | 49.0 | 97.0 | 58.0 | 149.5 | <0.001 |
Plasminogen (%) | 56.3 | 45.0 | 93.0 | 73.4 | 67.3 | 93.8 | 0.32 |
TNF-a (pg/mL) | 4.1 | 3.2 | 5.1 | 2.6 | 1.2 | 4.4 | 0.18 |
IL-1b (pg/mL) | 1.6 | 0.9 | 3.1 | 0.9 | 0.7 | 1.7 | 0.45 |
IL-10 (pg/mL) | 15.4 | 2.1 | 211.8 | 5.4 | 1.8 | 85.9 | 0.02 |
IL-6 (pg/mL) | 26.0 | 20.2 | 120.2 | 31.7 | 19.2 | 43.6 | 0.85 |
CRP (mg/dL) | 32.4 | 21.6 | 50.3 | 10.1 | 10.1 | 17.9 | <0.01 |
PCT (ng/mL) | 8.5 | 1.4 | 130,7 | 0.7 | 0.2 | 1.5 | <0.01 |
TPO (pg/mL) | 644 | 194 | 1344 | 160.0 | 40 | 519 | <0.01 |
Patients Who Deterioratedand Died (n = 17) | Patients Who Improved (n = 11) | p a | |||||
---|---|---|---|---|---|---|---|
Median | Range | Median | Range | ||||
Age (yrs) | 50 | 27 | 70 | 36 | 24 | 70 | 0.45 |
APACHE | 25.6 | 12.5 | 31.0 | 15.4 | 8.0 | 21.0 | <0.01 |
SOFA | 11.5 | 7.0 | 14.0 | 8.8 | 6.0 | 14.0 | 0.03 |
LIS | 2.5 | 0.2 | 3.9 | 1.1 | 0.2 | 2.0 | <0.01 |
PaO2/FiO2 (mmHg) | 103 | 70 | 320 | 248 | 136 | 325 | <0.01 |
MODS (yes/no) | 15/2 (88%) | 3/8(27%) | <0.01 b | ||||
Ht (%) | 26.4 | 19.3 | 31.0 | 28.5 | 15.0 | 36.5 | 0.59 |
PLT (×109/L) | 122 | 15 | 336 | 206 | 93 | 338 | 0.06 |
WBC (×109/L) | 18.6 | 6.4 | 41.3 | 13.8 | 11.0 | 31.3 | 0.69 |
Glu (mg/dL) | 160 | 138 | 223 | 133 | 104 | 222 | 0.33 |
Lactate (mmol/L) | 4.4 | 1.2 | 8.9 | 1.7 | 0.8 | 2.4 | <0.001 |
Creatin (mg/dL) | 2.3 | 0.5 | 9.0 | 1.2 | 0.4 | 2.2 | 0.13 |
Bil (mg/dL) | 3.1 | 0.5 | 18.9 | 0.9 | 0.2 | 3.1 | 0.08 |
Alb (g/dL) | 2.0 | 1.2 | 3.5 | 2.2 | 2.3 | 3.7 | 0.81 |
PT (sec) | 19.9 | 13.3 | 25.7 | 16.8 | 13.6 | 19.7 | 0.23 |
a-PTT (sec) | 55.1 | 35.1 | 180.0 | 36.7 | 27.8 | 51.7 | 0.12 |
Fibrin (mg/dL) | 458 | 439 | 700 | 644 | 444 | 699 | 0.24 |
Dds (μg/mL) | 10.8 | 1.8 | 37.6 | 4.1 | 1.9 | 14.6 | 0.06 |
FVII (%) | 30.5 | 29.0 | 61.0 | 58.3 | 40.0 | 80.0 | <0.001 |
FIX (%) | 82.2 | 75.0 | 112.0 | 101.0 | 95.0 | 128.0 | 0.03 |
FVIII (%) | 108.4 | 81.0 | 158.3 | 119.8 | 104.1 | 162.0 | 0.81 |
vWF(%) | 123.7 | 85.0 | 252.0 | 146.0 | 114.0 | 461.0 | 0.23 |
FX (%) | 73.4 | 66.0 | 117.5 | 90.0 | 75.00 | 119.0 | 0.12 |
FV (%) | 69.7 | 34.0 | 109.5 | 89.9 | 48.0 | 111.0 | 0.37 |
ATIII (%) | 30.7 | 23.0 | 83.0 | 57.6 | 38.0 | 113.0 | 0.21 |
PrC (%) | 48.0 | 12.0 | 68.0 | 63.0 | 47.5 | 125.0 | 0.01 |
Plasminogen (%) | 52.3 | 46.3 | 109.0 | 64.0 | 90.50 | 108.4 | 0.40 |
TNF-a (pg/mL) | 5.1 | 1.0 | 8.4 | 4.5 | 1.0 | 8.2 | 0.85 |
IL-1b (pg/mL) | 3.1 | 0.3 | 9.4 | 1.9 | 0.2 | 10.2 | 0.33 |
IL-10 (pg/mL) | 11.6 | 2.1 | 285.9 | 15.8 | 2.5 | 160.8 | 0.23 |
IL-6 (pg/mL) | 33.0 | 16.7 | 128.6 | 30.9 | 15.4 | 86.0 | 0.64 |
CRP (mg/dL) | 25.6 | 5.3 | 72.7 | 31.2 | 5.27 | 73.0 | 0.62 |
PCT (ng/mL) | 4.7 | 0.4 | 110.8 | 3.8 | 0.3 | 16.5 | 0.27 |
TPO (pg/mL) | 601 | 47 | 2213 | 487 | 42 | 774 | 0.18 |
Τrauma–Surgery | SIRS | Sepsis | Severe Sepsis | Septic Shock | |
---|---|---|---|---|---|
Age (yrs) | 0.66 (0.57–0.76) | ||||
APACHE | 0.84 (0.73–0.96) | 0.76 (0.65–0.88) | 0.83 (0.67–0.98) | ||
SOFA | 0.82 (0.65–0.99) | 0.73 (0.56–0.90) | 0.72 (0.55–0.89) | ||
LIS | 0.82 (0.66–1.00) | 0.80 (0.63–0.98) | 0.78 (0.65–0.90) | ||
PaO2/FiO2 (mmHg) | 0.67 (0.56–0.78) | 0.64 (0.44–0.83) | 0.90 (0.80–0.99) | 0.79 (0.66–0.92) | |
MODS (yes/no) | 0.91 (0.82–1.00) | ||||
Ht (%) | |||||
PLT (×109/L) | |||||
WBC (×109/L) | |||||
Glu (mg/dL) | |||||
Lactate (mmol/L) | 0.87 (0.79–0.94) | ||||
Creatin (mg/dL) | |||||
Bil (mg/dL) | |||||
Alb (g/dL) | |||||
PT (sec) | 0.75 (0.58–0.83) | ||||
a-PTT (sec) | |||||
Fibrin (mg/dL) | |||||
Dds (μg/mL) | 0.71 (0.64–0.79) | ||||
FVII (%) | 0.72 (0.49–0.83) | ||||
FIX (%) | 0.67 (0.53-0.78) | ||||
FVIII (%) | 0.63 (0.49–0.76) | ||||
vWF(%) | |||||
FX (%) | |||||
FV (%) | |||||
ATIII (%) | 0.74 (0.62–0.86) | ||||
PrC (%) | 0.75 (0.57–0.83) | 0.78 (0.60–0.95) | |||
Plasminogen (%) | |||||
TNF-a (pg/mL) | 0.76 (0.65–0.89) | 0.66 (0.53–0.76) | |||
IL-1b (pg/mL) | 0.71 (0.48–0.83) | ||||
IL-10 (pg/mL) | 0.72 (0.51–0.87) | ||||
IL-6 (pg/mL) | |||||
CRP (mg/dL) | 0.74 (0.60–0.89) | ||||
PCT (ng/mL) | 0.75 (0.56–0.89) | ||||
TPO (pg/mL) | 0.73 (0.46–0.91) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lavranou, G.-A.; Mentzelopoulos, S.; Katsaounou, P.; Siempos, I.; Kalomenidis, I.; Geranaki, A.; Routsi, C.; Zakynthinos, S. Can Coagulation System Disorders and Cytokine and Inflammatory Marker Levels Predict the Temporary Clinical Deterioration or Improvement of Septic Patients on ICU Admission? J. Clin. Med. 2021, 10, 1548. https://doi.org/10.3390/jcm10081548
Lavranou G-A, Mentzelopoulos S, Katsaounou P, Siempos I, Kalomenidis I, Geranaki A, Routsi C, Zakynthinos S. Can Coagulation System Disorders and Cytokine and Inflammatory Marker Levels Predict the Temporary Clinical Deterioration or Improvement of Septic Patients on ICU Admission? Journal of Clinical Medicine. 2021; 10(8):1548. https://doi.org/10.3390/jcm10081548
Chicago/Turabian StyleLavranou, Georgia-Athanasia, Spyros Mentzelopoulos, Paraskevi Katsaounou, Ilias Siempos, Ioannis Kalomenidis, Aikaterini Geranaki, Christina Routsi, and Spyros Zakynthinos. 2021. "Can Coagulation System Disorders and Cytokine and Inflammatory Marker Levels Predict the Temporary Clinical Deterioration or Improvement of Septic Patients on ICU Admission?" Journal of Clinical Medicine 10, no. 8: 1548. https://doi.org/10.3390/jcm10081548
APA StyleLavranou, G. -A., Mentzelopoulos, S., Katsaounou, P., Siempos, I., Kalomenidis, I., Geranaki, A., Routsi, C., & Zakynthinos, S. (2021). Can Coagulation System Disorders and Cytokine and Inflammatory Marker Levels Predict the Temporary Clinical Deterioration or Improvement of Septic Patients on ICU Admission? Journal of Clinical Medicine, 10(8), 1548. https://doi.org/10.3390/jcm10081548